SUNLOCSunil Healthcare Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Sunil Healthcare Limited engages in the manufacture and sale of empty hard gelatin, hydroxypropyl methylcellulose (HPMC), and pullulan capsules shells in India and internationally. Its products include EHG, BSE/TSE free, pearl, liquid fill, preservative free, stick free, flavored, SLS free, natural color, non-AZO, gelatin, HPMC/vegetable, and pullulan capsules. The company also provides ayurvedic products, such as haldi, ginger, vasaka, trifala, guduchi, salaki, punarvana, shatavari, hadjod, hingwastak, mulethi, arjuna, ashwagandha, and guggul extracts. The company offers its products under the SUNLOC brand name. Sunil Healthcare Limited was incorporated in 1973 and is based in New Delhi, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SUNLOC — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 33/100)
- • Revenue growth: -16.1% YoY
- • Profit growth: -49.4% YoY
- • Supertrend: bearish
- • Volume: 0.0x 20-day average
Bull case
- • Debt/Equity: 0.80
- • Promoter holding: 88.2%
- • Valuation vs sector: P/E 19.9 vs sector 35.5
- • MACD: fresh bullish crossover
Bear case
- • Revenue growth: -16.1% YoY
- • Profit growth: -49.4% YoY
- • Supertrend: bearish
- • Volume: 0.0x 20-day average
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -16.1% YoY
- • Profit growth: -49.4% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹3.08). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.